PHASE-II TRIAL OF FLUTAMIDE IN HYPER-NEPHROMA CORRELATION WITH HORMONE RECEPTOR-SITES

被引：0
|
作者：
BENEDETTO, P
YAGODA, A
WATSON, RC
SOGANI, P
NERI, RO
PERTSCHUK, LP
FISHMAN, J
BRADLOW, JL
机构：
[1] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021
[2] ROCKEFELLER UNIV,NEW YORK,NY 10021
[3] SUNY DOWNSTATE MED CTR,BROOKLYN,NY 11203
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1981年 / 22卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：466 / 466
页数：1
相关论文
共 50 条
  • [31] Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor-Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
    Carlson, Robert W.
    Theriault, Richard
    Schurman, Christine M.
    Rivera, Edgardo
    Chung, Cathie T.
    Phan, See-Chun
    Arun, Banu
    Dice, Kristine
    Chiv, Vivian Y.
    Green, Marjorie
    Valero, Vicente
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3917 - 3921
  • [32] A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2
    Friedland, D
    Cohen, J
    Miller, R
    Voloshin, M
    Gluckman, R
    Lembersky, B
    Zidar, B
    Keating, M
    Reilly, N
    Dimitt, B
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 19 - 23
  • [33] A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer
    Krop, Ian
    Abramson, Vandana
    Colleoni, Marco
    Traina, Tiffany
    Holmes, Frankie
    Garcia-Estevez, Laura
    Hart, Lowell
    Awada, Ahmad
    Zamagni, Claudio
    Morris, Patrick G.
    Schwartzberg, Lee
    Chan, Stephen
    Gucalp, Ayca
    Biganzoli, Laura
    Steinberg, Joyce
    Sica, Lorenzo
    Trudeau, Maureen
    Markova, Denka
    Tarazi, Jamal
    Zhu, Zhou
    O'Brien, Thomas
    Kelly, Catherine M.
    Winer, Eric
    Yardley, Denise A.
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6149 - 6157
  • [34] ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
    Emre Koca
    Polly Ann Niravath
    Joe Ensor
    Tejal Amar Patel
    Xiaoxian Li
    Pej Hemati
    Helen Wong
    Wei Qian
    Toniva Boone
    Jing Zhao
    Priya V. Ramshesh
    Adam Louis Cohen
    Asha Murthy
    Sindhu Nair
    Jorge German Darcourt
    Anna Belcheva
    Virginia G. Kaklamani
    Jenny Chee Ning Chang
    Breast Cancer Research and Treatment, 2021, 188 : 433 - 439
  • [35] Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
    Fontein, Duveken B. Y.
    Charehbili, Ayoub
    Nortier, Johan W. R.
    Kranenbarg, Elma Meershoek-Klein
    Kroep, Judith R.
    Putter, H.
    van Riet, Yvonne
    Nieuwenhuijzen, Grard A. P.
    de Valk, Bart
    Terwogt, Jetske M. Meerum
    Algie, Gijs D.
    Liefers, Gerrit-Jan
    Linn, Sabine
    van de Velde, Cornelis J. H.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2190 - 2200
  • [36] ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
    Koca, Emre
    Niravath, Polly Ann
    Ensor, Joe
    Patel, Tejal Amar
    Li, Xiaoxian
    Hemati, Pej
    Wong, Helen
    Qian, Wei
    Boone, Toniva
    Zhao, Jing
    Ramshesh, Priya, V
    Cohen, Adam Louis
    Murthy, Asha
    Nair, Sindhu
    Darcourt, Jorge German
    Belcheva, Anna
    Kaklamani, Virginia G.
    Chang, Jenny Chee Ning
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (02) : 433 - 439
  • [37] A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer
    Danciu, Oana C.
    Hoskins, Kent
    Weiss, Jennifer
    Truica, Cristina I.
    Blaes, Anne
    Tamkus, Deimante
    Rana, Jatin
    Pavankumar, Tandra
    Green, Lauren
    Gao, Yu
    Yu, Menggang
    Zhao, Qianqian
    Toppmeyer, Deborah
    O'Regan, Ruth
    Wisinski, Kari B.
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
    Azim, Hamdy A.
    Saleh, Mariam A.
    Eldin, Passant Essam
    Abdelhafeez, Ahmed A. M.
    Hassan, Mohamed
    Kassem, Loay
    JOURNAL OF CHEMOTHERAPY, 2025, 37 (02) : 159 - 167
  • [39] A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer
    Traina, TA
    Dickler, MN
    Caravelli, JF
    Yeh, BM
    Brogi, E
    Panageas, K
    Flores, SA
    Norton, L
    Park, J
    Hudis, C
    Rugo, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S93 - S94
  • [40] Palbociclib Rechallenge for Hormone Receptor- Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
    Albanell, Joan
    Manuel Perez-Garcia, Jose
    Gil-Gil, Miguel
    Curigliano, Giuseppe
    Ruiz-Borrego, Manuel
    Comerma, Laura
    Gibert, Joan
    Bellet, Meritxell
    Bermejo, Begona
    Calvo, Lourdes
    de la Haba, Juan
    Espinosa, Enrique
    Marco Minisini, Alessandro
    Quiroga, Vanesa
    Santaballa Bertran, Ana
    Mina, Leonardo
    Bellosillo, Beatriz
    Rojo, Federico
    Menendez, Silvia
    Sampayo-Cordero, Miguel
    Popa, Crina
    Malfettone, Andrea
    Cortes, Javier
    Llombart-Cussac, Antonio
    CLINICAL CANCER RESEARCH, 2022, 29 (01) : 67 - 80
12345